Quest Diagnostics raises 2024 outlook; Q2 reported EPS falls 1.0% to $2.03
Quest Diagnostics reported second-quarter 2024 net revenues of $2.40 billion, up 2.5% from a year earlier, and raised its full-year 2024 revenue and adjusted diluted EPS guidance. Reported diluted EPS fell 1.0% to $2.03, while adjusted diluted EPS rose 2.2% to $2.35, so shareholders see higher sales and adjusted earnings alongside lower reported profit. The updated guidance excludes the pending LifeLabs acquisition.
Key points
- Q2 2024 net revenues $2.40 billion, up 2.5%; net income attributable to Quest Diagnostics $229 million, down 2.4%
- Q2 reported diluted EPS $2.03, down 1.0%; adjusted diluted EPS $2.35, up 2.2%
- Full-year 2024 net revenues now expected at $9.50 billion to $9.58 billion, up from $9.40 billion to $9.48 billion
- Full-year adjusted diluted EPS now expected at $8.80 to $9.00, up from $8.72 to $8.97; reported diluted EPS range $7.57 to $7.77, high end down from $7.82
The filing
Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 23, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.